Biliverdin Reductase A in Chronic Hepatitis C Virus Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01112033|
Recruitment Status : Completed
First Posted : April 28, 2010
Last Update Posted : August 7, 2015
|Condition or disease|
|Hepatitis C, Chronic|
- To analyze biliverdin reductase (BLVRA) expression in the liver of HVC infected patients undergoing liver biopsy followed by standard antiviral treatment (peg-interferon plus ribavirin combination therapy) and patients with other forms of liver diseases undergoing liver biopsy as controls.
- To analyze BLVRA expression in peripheral blood leukocytes (PBL) of therapeutically naïve HCV patients, during/after standard antiviral therapy and healthy controls.
- To analyze BVLRA genetic polymorphisms both in HCV infected patients and healthy controls.
|Study Type :||Observational|
|Actual Enrollment :||113 participants|
|Observational Model:||Case Control|
|Official Title:||Biliverdin Reductase A in Chronic Hepatitis C Virus Infection|
|Study Start Date :||June 2010|
|Primary Completion Date :||March 2013|
|Study Completion Date :||June 2013|
chronic HCV infection
The study was performed on therapeutically naïve patients with chronic HCV infection. Patients with positivity of anti-HCV antibodies, and detectable HCV RNA in serum for at least 6 months, were included in the study.
- To assess differences in BLVRA expression in the liver and PBMC in HCV infected patients in responders and non-responders to standard antiviral therapy. [ Time Frame: 72 weeks ]
- To analyze the association of genetic polymorphisms of BLVRA with disease progression and treatment response in HCV infected patients. [ Time Frame: 3 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01112033
|Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague|
|Prague, Czech Republic, 128 60|
|Principal Investigator:||Iva Subhanova||Charles University|